

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BOEHRINGER INGELHEIM
PHARMACEUTICALS INC., BOEHRINGER
INGELHEIM INTERNATIONAL GMBH and
BOEHRINGER INGELHEIM PHARMA
GMBH & CO. KG,

Plaintiffs,

v.

BIOCON LIMITED, BIOCON PHARMA,
INC. AND BIOCON PHARMA LIMITED,

Defendants.

C.A. No. 25-523-CFC

ANDA CASE

RULE 7.1 DISCLOSURE STATEMENT

Pursuant to Federal Rule of Civil Procedure 7.1 and Chief Judge Connolly's Standing Order Regarding Disclosure Statements Required by Federal Rule of Civil Procedure 7.1, the undersigned counsel for Defendants Biocon Limited, Biocon Pharma Limited, and Biocon Pharma, Inc. certifies as follows:

1. Defendant Biocon Pharma, Inc. is a Delaware corporation that is a wholly-owned subsidiary of Biocon Pharma Limited;
2. Defendant Biocon Pharma Limited is organized under the laws of India and is a wholly-owned subsidiary of Biocon Limited; and
3. Defendant Biocon Limited is organized under the laws of India and is publicly-held. Biocon shares are traded on the National Stock Exchange (NSE) and the Mumbai Stock Exchange (BSE). There is no parent corporation or publicly held corporation owning more than 10% or more of its stock.

Dated: July 28, 2025

SMITH, KATZENSTEIN & JENKINS LLP

/s/ Neal C. Belgam

Neal C. Belgam (No. 2721)

Daniel A. Taylor (No. 6934)

1000 West Street, Suite 1501

Wilmington, DE 19801

(302) 652-8400

nbelgam@skjlaw.com

dtaylor@skjlaw.com

*Counsel for Defendants Biocon Limited,
Biocon Pharma Limited, and Biocon Pharma,
Inc.*